1. Introduction {#j_med-2019-0100_s_001}
===============

Balanced reciprocal translocations are structural chromosomal abnormalities. Male carriers may have high rates of genetically unbalanced spermatozoa and exhibit impaired spermatogenesis, associated with frequent unbalanced embryos, male infertility or increased miscarriages \[[@j_med-2019-0100_ref_001], [@j_med-2019-0100_ref_002], [@j_med-2019-0100_ref_003]\]. However, clinical cases of normal male fertility with no history of related abortion can also be found for individuals with balanced translocations. Additionally, although in vitro fertilization accompanied by preimplantation genetic diagnosis (PGD) increased the chance of translocation carriers fathering a healthy child \[[@j_med-2019-0100_ref_004]\], some studies suggested that PGD did not make better for live birth rate and repeated miscarriage of couples with balanced translocations \[[@j_med-2019-0100_ref_005],[@j_med-2019-0100_ref_006]\]. Natural conception is still a possible option for these carriers' couples \[[@j_med-2019-0100_ref_007],[@j_med-2019-0100_ref_008]\]. Hence, genetic counselling remains a challenge for carriers of balanced translocations.

Recently, we reported and reviewed the relationship between translocation breakpoints of chromosomes 2, 3, 5, and 6, and infertility for male carriers \[[@j_med-2019-0100_ref_009], [@j_med-2019-0100_ref_010], [@j_med-2019-0100_ref_011], [@j_med-2019-0100_ref_012], [@j_med-2019-0100_ref_013]\]. Previous studies indicated that chromosome 9 translocations are involved in reduced male fertility and increased chance of miscarriage in the female partner \[[@j_med-2019-0100_ref_004],[@j_med-2019-0100_ref_014],[@j_med-2019-0100_ref_015]\]. The chromosomes and specific breakpoints involved in the translocation are closely related to reproductive abnormalities \[[@j_med-2019-0100_ref_016],[@j_med-2019-0100_ref_017]\]. Chromosomal translocation can increase the frequency of spermatozoa carrying an abnormal chromosome constitution, and some translocation breakpoints can disrupt important genes involved in spermatogenesis \[[@j_med-2019-0100_ref_010]\]. Testis-specific protein kinase 1 gene (*TESK1*) is located on chromosome 9p13.3 and is specifically expressed in testicular germ cells \[[@j_med-2019-0100_ref_018]\]. Thioredoxin domain-containing protein 8 gene (*TXNDC8*), mapped to chromosome 9q31.3, may be associated with late sperm maturation \[[@j_med-2019-0100_ref_019]\]. Additionally, chromosome 9 was the first chromosome found to be frequently associated with infertile patients \[[@j_med-2019-0100_ref_020]\]. Understanding the breakpoints on chromosome 9 with respect to providing genetic counselling for male infertility warrants further research.

The aim of this study is to identify potential correlations between clinical characteristics of male infertility and carriers of specific translocation breakpoints in chromosome 9.

2. Methods {#j_med-2019-0100_s_002}
==========

Twelve male carriers of chromosome 9 translocations experiencing infertility or receiving counselling were recruited from the outpatient's department at the Center for Reproductive Medicine, First Hospital of Jilin University, Changchun, China between July 2010 and December 2017. This study included all translocation cases involving chromosome 9, and excluded the patients with varicocele, ejaculatory duct obstruction and the other cause of infertility. Each patient underwent semen and cytogenetic analysis. Abortions due to the female factor were excluded. This study was approved by the Ethics Committee of the First Hospital of Jilin University, and written informed consent was provided by each patient.

For each patient, a semen sample obtained by masturbation after 3-7 days of abstinence was allowed to liquefy at room temperature, and was then analyzed using standard techniques recommended by the World Health Organization guidelines. Patients with oligozoospermia were diagnosed with a sperm count less than 15×106/ml in their last three semen samples (taken at intervals of 1--3 weeks). Oligozoospermia and severe oligozoospermia were defined as previously described \[[@j_med-2019-0100_ref_002]\]. Chromosome preparations were obtained from lymphocyte cultures derived from each patient. Karyotype analysis after G-banding of metaphase chromosomes followed our previously reported methods \[[@j_med-2019-0100_ref_011]\].

Male chromosome 9 translocations and specific breakpoints from reported papers were searched using PubMed, Google Scholar and CNKI database. The search keywords were "chromosome/ translocation/sperm" and "chromosome/translocation/ abortion". This study included male cases of adult fertile-age, and excluded females and newborns carriers, those with complex chromosomal translocations, chimeras or bone marrow detection, and other cases without breakpoints involving chromosome 9 in the reported papers.

3. Results {#j_med-2019-0100_s_003}
==========

This study clinically examined a total of 12 men with chromosome 9 translocations. Karyotype results and G-banding karyotypes from these 12 patients are shown in [Table 1](#j_med-2019-0100_tab_001){ref-type="table"} and [Figure 1](#j_med-2019-0100_fig_001){ref-type="fig"}, respectively. Three cases had oligozoospermia or severe oligozoospermia (pregestational infertility), while nine cases had normal semen. Of the former three cases, the carrier with t(1; 9) (p32; p24) showed oligozoospermia, and the other two carriers manifested severe oligozoospermia. After genetic counselling and informed consent, the use of intracytoplasmic sperm injection combined with PGD should be carefully considered for these patients. Of the latter nine cases, it was evident that the carriers' wife had a tendency to miscarry (gestational infertility); two cases with t(3;9)(q21;q22) and t(8;9)(q24;q32) produced a phenotypically normal child as confirmed by amniocentesis, respectively, and the other seven cases had experienced recurrent miscarriage. For these patients, PGD or prenatal diagnosis should be considered to improve pregnancy rates and reduce abortion rates.

![G-banding karyotypes of the 12 cases identified as possessing chromosome 9 translocations. a: t(1;9) (p22;p24); b: t(1;9) (p32;p24); c: t(9;15) (p13;q11); d: t(1;9); e: t(3;9); f: t(4;9); g: t(6;9); h: t(8;9); i: t(5;9); j: t(7;9); k: t(9;15) (p24;q22); l: t(9;10).](med-14-854-g001){#j_med-2019-0100_fig_001}

###### 

Karyotypes of chromosome 9 translocation carriers and their clinical features

  Infertility type   Clinical findings                                                     Karyotype                Figure No.
  ------------------ --------------------------------------------------------------------- ------------------------ -------------------------------------------------------
  Pregestational     Oligozoospermia or severe oligozo- ospermia                           46,XY,t(1;9)(p22;p24)    [Figure 1a](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(1;9)(p32;p24)    [Figure 1b](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(9;15)(p13;q11)   [Figure 1c](#j_med-2019-0100_fig_001){ref-type="fig"}
  Gestational        Normal sperm density; a history of miscarriage or Natural pregnancy   46,XY,t(1;9)(p36;q32)    [Figure 1d](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(3;9)(q21;q22)    [Figure 1e](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(4;9)(q35;p13)    [Figure 1f](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(6;9)(q26;p13)    [Figure 1g](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(8;9)(q24;q32)    [Figure 1h](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(5;9)(p13;q22)    [Figure 1i](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(7;9)(p10;q10)    [Figure 1j](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(9;15)(p24;q22)   [Figure 1k](#j_med-2019-0100_fig_001){ref-type="fig"}
                                                                                           46,XY,t(9;10)(q21;q22)   [Figure 1l](#j_med-2019-0100_fig_001){ref-type="fig"}

From a review of the literature, clinical feature, karyotype, and specific breakpoints on chromosome 9 were collected and are summarized in [Table 2](#j_med-2019-0100_tab_002){ref-type="table"}. The reported paper included 76 carriers of chromosome 9 translocations. Combined with the 12 cases reported in this study, chromosome 1 (11 cases) is the most frequently involved with chromosome 9 translocation. In cases of male infertility, the distribution of other chromosomes involved in the translocation with chromosome 9 is shown in [Figure 2](#j_med-2019-0100_fig_002){ref-type="fig"}. The distribution suggests that balanced translocation is closely related to male fertility, and multiple breakpoints on chromosome 1 are involved in these translocations. However, chromosome 11 was not found to be involved in translocation with chromosome 9.

![Distribution of chromosomes involved in translocations with chromosome 9.](med-14-854-g002){#j_med-2019-0100_fig_002}

###### 

Breakpoints in chromosome 9 translocation carriers and clinical features reported in previous literature

  Cases   Karyotype   Breakpoints        Clinical findings                       Reference
  ------- ----------- ------------------ --------------------------------------- -----------------------------------------------------------
  1       t(1;9)      1q11;9p24          severe oligozoospermia                  Yoshida et al., 1997 \[[@j_med-2019-0100_ref_075]\]
  2       t(1;9)      1q43; 9p23         Oligoasthenozoospermia                  Perrin et al., 2013 \[[@j_med-2019-0100_ref_045]\]
  3       t(1;9)      1q11; 9p13         Azoospermia or severe oligozoospermia   Mierla et al., 2014 \[[@j_med-2019-0100_ref_014]\]
  4       t(1;9)      1q12; 9q13         PGD                                     Zhang et al., 2014 \[[@j_med-2019-0100_ref_081]\]
  5       t(1;9)      1q23; 9q22.3       Recurrent miscarriage                   Dutta et al., 2011 \[[@j_med-2019-0100_ref_038]\]
  6       t(1;9)      1q42.3; 9q22.3     Recurrent miscarriage                   Sugiura-Ogasawara., 2008\[[@j_med-2019-0100_ref_056]\]
  7       t(1;9)      1q22; 9q31         Infertility                             Martin, 1992 \[[@j_med-2019-0100_ref_061]\]
  8       t(1;9)      1p32.1; 9q34.3     Normal sperm count                      Matsuda et al., 1992 \[[@j_med-2019-0100_ref_036]\]
  9       t(2;9)      2q21; 9p22         Infertility                             Martin et al., 1990 \[[@j_med-2019-0100_ref_060]\]
  10      t(2;9)      2q32; 9q31         ICSI                                    Gekas et al., 2001 \[[@j_med-2019-0100_ref_052]\]
  11      t(2;9)      2q33; 9q34         PGD                                     Findikli et al., 2003 \[[@j_med-2019-0100_ref_051]\]
  12      t(2;9)      2q37; 9q22         2 fetal losses                          Adamoli et al., 1986 \[[@j_med-2019-0100_ref_042]\]
  13      t(2;9)      2q37.3; 9q12       Normal semen                            Dul et al., 2012 \[[@j_med-2019-0100_ref_054]\]
  14      t(3;9)      3p25; 9q32         Infertility                             Honda et al., 1999 \[[@j_med-2019-0100_ref_064]\]
  15      t(3;9)      3q21; 9q34         PGD                                     Findikli et al., 2003 \[[@j_med-2019-0100_ref_051]\]
  16      t(3;9)      3q26.2; 9q32       Infertility                             Honda et al., 1999 \[[@j_med-2019-0100_ref_064]\]
  17      t(3;9)      3q28; 9q32         Azoospermia or severe oligozoospermia   Mierla et al., 2014 \[[@j_med-2019-0100_ref_014]\]
  18      t(4;9)      4p15.2; 9p13       Recurrent spontaneous abortions         Celep et al., 2006 \[[@j_med-2019-0100_ref_078]\]
  19      t(4;9)      4q23.2; 9q22.3     Recurrent pregnancy loss                Kochhar et al., 2013 \[[@j_med-2019-0100_ref_015]\]
  20      t(4;9)      4q25; 9p22         Infertility                             Moretti et al., 2009 \[[@j_med-2019-0100_ref_073]\]
  21      t(4;9)      4q31.1; 9p24       Recurrent spontaneous abortions         Celep et al., 2006 \[[@j_med-2019-0100_ref_078]\]
  22      t(5;9)      5p15.1; 9q22.1     Primary infertility                     Vozdova et al., 2013 \[[@j_med-2019-0100_ref_004]\]
  23      t(5;9)      5p13; 9q22         PGD                                     Zhang et al., 2014 \[[@j_med-2019-0100_ref_081]\]
  24      t(5;9)      5p12; 9p11         Infertility                             Pellestor et al., 2001 \[[@j_med-2019-0100_ref_066]\]
  25      t(5;9)      5q10; 9q10         Infertility                             Rouen et al., 2017 \[[@j_med-2019-0100_ref_035]\]
  26      t(5;9)      5q23.2; 9q22.3     Spontaneous abortion                    Stephenson et al., 2006 \[[@j_med-2019-0100_ref_048]\]
  27      t(5;9)      5q23.3; 9p24       Repeated miscarriages                   Iyer et al., 2007 \[[@j_med-2019-0100_ref_055]\]
  28      t(6;9)      6p12; 9q13         PGD, No pregnancy                       Escudero et al., 2003 \[[@j_med-2019-0100_ref_076]\]
  29      t(7;9)      7p15.2; 9q34.1     Primary infertility                     Vozdova et al., 2013 \[[@j_med-2019-0100_ref_004]\]
  30      t(7;9)      7p14.2; 9q32       Recurrent miscarriage                   Pundir et al., 2016 \[[@j_med-2019-0100_ref_057]\]
  31      t(7;9)      7p13; 9p23         ICSI                                    Gekas et al., 2001 \[[@j_med-2019-0100_ref_052]\]
  32      t(7;9)      7p13; 9q21         Teratozoospermia                        Rouen et al., 2013\[[@j_med-2019-0100_ref_039]\]
  33      t(7;9)      7q31; 9q34         Early miscarriage                       Olszewska et al., 2017 \[[@j_med-2019-0100_ref_043]\]
  34      t(7;9)      7q33; 9p21         Infertility                             Pellestor et al., 1997 \[[@j_med-2019-0100_ref_063]\]
  35      t(7;9)      7q36.2; 9p21.2     Normal semen                            Wiland et al., 2008 \[[@j_med-2019-0100_ref_074]\]
  36      t(8;9)      8p21; 9p24         Spontaneous abortions                   Bourrouillou et al., 1986 \[[@j_med-2019-0100_ref_047]\]
  37      t(8;9)      8p21; 9q34         Early miscarriage                       Olszewska et al., 2017 \[[@j_med-2019-0100_ref_043]\]
  38      t(8;9)      8q24.2; 9q32       Infertility                             Estop et al., 1998 \[[@j_med-2019-0100_ref_068]\]
  39      t(8;9)      8q24.3; 9p21.2     Severe oligozoospermia;                 Olszewska et al., 2017 \[[@j_med-2019-0100_ref_043]\]
  40      t(8;9)      8q24.2; 9q32       Infertility                             Estop et al., 2000 \[[@j_med-2019-0100_ref_065]\]
  41      t(8;9)      8q24.3; 9p24       Infertility                             Ferfouri et al., 2013 \[[@j_med-2019-0100_ref_071]\]
  42      t(9;10)     9q11; 10p11.1      Repetitive abortions                    Rives et al., 2003 \[[@j_med-2019-0100_ref_067]\]
  43      t(9;10)     9q12; 10q26        Azoospermia or severe oligozoospermia   Mierla et al., 2014 \[[@j_med-2019-0100_ref_014]\]
  44      t(9;10)     9q34; 10q11        Infertility                             Martin, 1988 \[[@j_med-2019-0100_ref_059]\]
  45      t(9;10)     9q34.3; 10q24.1    PGD                                     Ko et al., 2010 \[[@j_med-2019-0100_ref_040]\]
  46      t(9;12)     9p22; 12q22        Recurrent fetal wastage                 Fryns et al., 1998 \[[@j_med-2019-0100_ref_079]\]
  47      t(9;13)     9p23; 13q21.1      PGD                                     Ko et al., 2010 \[[@j_med-2019-0100_ref_040]\]
  48      t(9;13)     9q21.1; 13q21.2    Infertility                             Martin et al., 1995 \[[@j_med-2019-0100_ref_062]\]
  49      t(9;13)     9q31; 13q34        Recurrent pregnancy loss                Kochhar et al., 2013 \[[@j_med-2019-0100_ref_015]\]
  50      t(9;13)     9q32; 13q32        Recurrent miscarriage                   Sugiura-Ogasawara., 2008 \[[@j_med-2019-0100_ref_056]\]
  51      t(9;14)     9p13; 14q13        Normal semen                            Wiland et al., 2008 \[[@j_med-2019-0100_ref_074]\]
  52      t(9;14)     9q22.1; 14q12      Infertility                             Gada Saxena et al., 2012 \[[@j_med-2019-0100_ref_080]\]
  53      t(9;14)     9q32; 14p11.2      Severe oligozoospermia                  Brugnon et al., 2006 \[[@j_med-2019-0100_ref_049]\]
  54      t(9;15)     9p10; 15q10        Oligoasthenoteratozoospermia            Aydos et al., 2006 \[[@j_med-2019-0100_ref_072]\]
  55      t(9;15)     9q32; 15q24        Multiple Abortions                      Castle et al., 1988 \[[@j_med-2019-0100_ref_041]\]
  56      t(9;16)     9q34.2; 16p12      Normal semen                            Douet-Guilbert et al.,2005 \[[@j_med-2019-0100_ref_050]\]
  57      t(9;17)     9p13; 17q21.3      Normal sperm count                      Perrin et al., 2009 \[[@j_med-2019-0100_ref_077]\]
  58      t(9;17)     9p13; 17q21.3      Infertility                             Benet et al., 2005 \[[@j_med-2019-0100_ref_070]\]
  59      t(9;17)     9p12; 17q24        Oligozoospermia                         Antonelli et al., 2000 \[[@j_med-2019-0100_ref_046]\]
  60      t(9;17)     9q12; 17p12        Infertility                             Benet et al., 2005 \[[@j_med-2019-0100_ref_070]\]
  61      t(9;17)     9q21; 17p11.2      PGD, Delivery                           Kyu Lim et al., 2004 \[[@j_med-2019-0100_ref_037]\]
  62      t(9;17)     9q22; 17p13        Normal semen                            Brugnon et al., 2006 \[[@j_med-2019-0100_ref_049]\]
  63      t(9;17)     9q22.1; 17p13.1    Repeated spontaneous abortions          Ghazaey et al., 2015 \[[@j_med-2019-0100_ref_003]\]
  64      t(9;18)     9p12; 18q12.1      Infertility                             Pellestor et al., 1989 \[[@j_med-2019-0100_ref_044]\]
  65      t(9;18)     9q22.2; 18p11.31   Recurrent miscarriage                   Pundir et al., 2016 \[[@j_med-2019-0100_ref_057]\]
  66      t(9;18)     9q32; 18q23        Recurrent miscarriage                   Pundir et al., 2016 \[[@j_med-2019-0100_ref_057]\]
  67      t(9;19)     9q10; 19p10        Increased aneuploid sperm               Godo et al., 2013 \[[@j_med-2019-0100_ref_017]\]
  68      t(9;19)     9q10; 19p10        Not recorded                            Anton et al., 2008 \[[@j_med-2019-0100_ref_053]\]
  69      t(9;20)     9p24; 20q13.1      Oligozoospermia and astenozoospermia    Anton et al., 2008 \[[@j_med-2019-0100_ref_053]\]
  70      t(9;20)     9q13.4;20p11.2     Normal sperm count                      Yoshida et al., 1997 \[[@j_med-2019-0100_ref_075]\]
  71      t(9;21)     9p21; 21q22        Recurrent abortion                      Gaboon et al., 2015 \[[@j_med-2019-0100_ref_058]\]
  72      t(9;21)     9p13; 21q22.1      PGD                                     Zhang et al., 2014 \[[@j_med-2019-0100_ref_081]\]
  73      t(9;21)     9q11; 21q10        IVF                                     Findikli et al., 2003 \[[@j_med-2019-0100_ref_051]\]
  74      t(9;22)     9q21; 22q11.2      Oligospermia and asthenospermia         Perrin et al., 2009 \[[@j_med-2019-0100_ref_077]\]
  75      t(9;22)     9q21; 22q11.2      Oligozoospermia                         Douet-Guilbert et al.,2005 \[[@j_med-2019-0100_ref_050]\]
  76      t(9;22)     9q21; 22q11.2      Infertility                             Morel et al., 2004 \[[@j_med-2019-0100_ref_069]\]

The breakpoints at 9q32, 9p24 and 9p13 were observed in 12 cases (13.6%), 10 cases (11.4%) and 9 cases (10.2%) respectively. The breakpoints at 9p12, 9p11, 9p10 and 9q34.1 were related to pregestational infertility, while breakpoints at 9p21, 9q10, 9q11, 9q13, 9q21.1, 9q22, 9q22.2, 9q22.3, 9q34, 9q34.2 and 9q34.3 exhibited gestational infertility. Other breakpoints were found with cases of either pregestational or gestational infertility ([Table 3](#j_med-2019-0100_tab_003){ref-type="table"}).

###### 

Incidence of breakpoints on chromosome 9

  Breakpoints   Number of patients with pre-gestational infertility   Number of p atients with gestational infertility   Total (%)
  ------------- ----------------------------------------------------- -------------------------------------------------- -----------
  p24           5                                                     5                                                  10(11.4%)
  p23           2                                                     1                                                  3(3.4%)
  p22           2                                                     1                                                  3(3.4%)
  p21.2         1                                                     1                                                  2(2.3%)
  p21                                                                 2                                                  2(2.3%)
  p13           2                                                     7                                                  9(10.2%)
  p12           2                                                                                                        2(2.3%)
  p11           1                                                                                                        1(1.1%)
  p10           1                                                                                                        1(1.1%)
  q10                                                                 3                                                  3(3.4%)
  q11                                                                 2                                                  2(2.3%)
  q12           1                                                     2                                                  3(3.4%)
  q13                                                                 2                                                  2(2.3%)
  q13.4                                                               1                                                  1(1.1%)
  q21           4                                                     2                                                  6(6.8%)
  q21.1                                                               1                                                  1(1.1%)
  q22                                                                 5                                                  5(5.7%)
  q22.1         1                                                     2                                                  3(3.4%)
  q22.2                                                               1                                                  1(1.1%)
  q22.3                                                               4                                                  4(4.5%)
  q31           2                                                     1                                                  3(3.4%)
  q32           3                                                     9                                                  12(13.6%)
  q34                                                                 5                                                  5 (5.7 %)
  q34.1         1                                                                                                        1 (1.1 %)
  q34.2                                                               1                                                  1 (1.1 %)
  q34.3                                                               2                                                  2 (2.3%)

4. Discussion {#j_med-2019-0100_s_004}
=============

This study reports the karyotype and clinical manifestations of 12 cases with chromosome 9 translocations. Three cases had oligozoospermia or severe oligozoospermia, seven cases were associated with recurrent spontaneous abortions, and two cases each produced a phenotypically normal child (confirmed by amniocentesis). Pregestational and gestational infertility are the most typical two types for infertile male \[[@j_med-2019-0100_ref_021]\]. This study included three cases that exhibited pregestational infertility, and seven cases that exhibited gestational infertility. These patients may consider intracytoplasmic sperm injection or PGD combined within vitro fertilization to reduce subsequent miscarriage rate. The two cases that produced a phenotypically normal child indicated that carriers have a chance of natural conception. The live birth rate in patients with chromosomal translocations choosing to conceive naturally was reported to be 37--63% for the first pregnancy, and then a cumulative rate of 65--83% \[[@j_med-2019-0100_ref_022]\].

To study the role of breakpoints on chromosome 9 in male infertility, the previously published literatures were reviewed. The clinical findings and karyotype regarding chromosome 9 are shown in [Table 2](#j_med-2019-0100_tab_002){ref-type="table"}. For all carriers from our study and reported literature, the most common chromosome and breakpoint involved chromosome 9 translocation were t(1;9) (12.5%) and 9q32 (13.6%) respectively. Chromosome 1 was most involved with chromosome 9 translocation in this study. For translocation carriers involved in chromosome 1, the clinical phenotype is more likely to be related to chromosome 1. Previous literatures have reported that there are more genes related to spermatogenesis on chromosome 1 \[[@j_med-2019-0100_ref_023],[@j_med-2019-0100_ref_024]\]. The breakpoints on chromosome 1 could interfere with spermatogenesis, leading to azoospermia. In genetic counselling, the breakpoints on chromosome 1 should be considered for the translocation carriers involved in t (1; 9).

Breakpoints at 9p12, 9p11, 9p10 and 9q34.1 were found with pregestational infertility, while breakpoints at 9p21, 9q10, 9q11, 9q13, 9q21.1, 9q22, 9q22.2, 9q22.3, 9q34, 9q34.2 and 9q34.3 exhibited gestational infertility. Therefore, more chromosome 9 breakpoints exhibited gestational (compared with pregestational) infertility, in which the carriers' wife had a tendency to miscarry. Other breakpoints were found with cases of pregestational or gestational infertility. Previous studies have shown that certain genes on chromosome 9 are involved in spermatogenesis. For example, the aquaporin 7 gene (*AQP7*), located on chromosome 9p13.3, is expressed during the late stages of spermatogenesis \[[@j_med-2019-0100_ref_025]\]. Spermatogenic failure 8 gene (*SPGF8*), mapped to chromosome 9q33.3, is associated with severe spermatogenic failure \[[@j_med-2019-0100_ref_026]\]. The outer dense fiber of sperm tails 2 gene (*ODF2*), mapped to chromosome [9q34.11]{.ul}, has a key role in the formation of sperm flagella \[[@j_med-2019-0100_ref_027]\]. Doublesex-and mab3-related transcription factor 1 (*DMRT1*) and *DMRT3*, mapped to chromosome 9p24.3, are expressed in germ cell and Sertoli cells \[[@j_med-2019-0100_ref_028]\]. Relaxin 1 (*RLN 1*) and RLN2, mapped to chromosome 9p24.1, are highly expressed in the prostate and testis \[[@j_med-2019-0100_ref_029]\]. Lysine-specific demethylase 4c (*KDM4C*) located on chromosome 9p24.1 regulates histone modifications and androgen receptor function \[[@j_med-2019-0100_ref_030]\]. Testis expressed 48 (TEX 48) and TEX53, mapped to chromosome 9q32, are testis-specific genes \[[@j_med-2019-0100_ref_031]\]. The specific function of these genes needs further investigation. Kim et al \[[@j_med-2019-0100_ref_032]\] reported that breakpoints at 9p22; 9p11.2, 9q21.2 and 9q22 were found with cases of impaired spermatogenesis, and breakpoints at 9p23.24, 9p23, 9p12 and 9q22 were associated with recurrent abortion. The key difference between the above paper and our current study is that their subjects had complex chromosomal rearrangements. The carrier is more likely to have normal sperm in semen when they involve balanced translocation of two chromosomes. For the carriers of complex chromosomal rearrangements, the probability of abnormal spermatogenesis increase greatly.

Male carriers of chromosome translocations are phenotypically normal, but may produce genetically unbalanced spermatozoa, leading to unbalanced embryos and miscarriage. Translocations may alter the process of spermatogenesis, resulting in azoospermia or oligospermia \[[@j_med-2019-0100_ref_033]\]. To explain the associated clinical pregestational or gestational infertility, three hypotheses have been proposed, including a break within a gene, a positional effect, and cryptic deletion or duplication \[[@j_med-2019-0100_ref_034]\]. During genetic counselling, physicians should consider the breakpoints involved in the translocation. When receiving genetic counselling, the carriers of chromosome 9 translocations should consider suitable reproductive options, including continued attempts at natural conception or in vitro fertilization accompanied by PGD.

Limitations of this study include the small number of carriers of chromosome 9 translocations, and the lack of detailed research regarding the specific molecular effects of each translocation by molecular-cytogenetic methods. According to our knowledge, this study is the first review of male carriers involved in chromosome 9 translocation published in previous literature, which will provide reference for clinical genetic counselling.

5. Conclusion {#j_med-2019-0100_s_005}
=============

In the present study, the most common breakpoints involving chromosome 9 translocation were t(1;9) and 9q32 respectively. Most breakpoints at chromosome 9 exhibited gestational infertility. Carriers of chromosome 9 translocations should be counselled to consider in vitro fertilization accompanied by PGD.
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